Beautiful Virgin Islands

Tuesday, Jun 03, 2025

First pill to treat Covid gets approval in UK

First pill to treat Covid gets approval in UK

The first pill designed to treat symptomatic Covid has been approved by the UK medicines regulator.

The tablet - molnupiravir - will be given twice a day to vulnerable patients recently diagnosed with the disease.

In clinical trials the pill, originally developed to treat flu, cut the risk of hospitalisation or death by about half.

Health Secretary Sajid Javid said the treatment was a "gamechanger" for the most frail and immunosuppressed.

In a statement he said: "Today is a historic day for our country, as the UK is now the first country in the world to approve an antiviral that can be taken at home for Covid."

First oral treatment


Molnupiravir, developed by the US drug companies Merck, Sharp and Dohme (MSD) and Ridgeback Biotherapeutics, is the first antiviral medication for Covid which can be taken as a pill rather than injected or given intravenously.

The UK has agreed to purchase 480,000 courses with the first deliveries expected in November.

Initially it will be given to both vaccinated and unvaccinated patients through a national study, with extra data on its effectiveness collected before any decision to order more.

The drug needs to be given within five days of symptoms developing to be most effective.

It's not immediately clear how it will be distributed so quickly by the NHS. It's thought some care homes may be offered supplies while other elderly or vulnerable patients may be prescribed it by their GP after testing positive for Covid.

Molnupiravir, developed by scientists at Ridgeback Biotherapeutics and MSD, is the first of a number of oral antiviral treatments for Covid to report clinical trial results.


The new treatment targets an enzyme that the virus uses to make copies of itself, introducing errors into its genetic code. That should prevent it from multiplying, so keeping virus levels low in the body and reducing the severity of the disease.

Merck said that approach should make the treatment equally effective against new variants of the virus as it evolves in the future.

The UK regulator, the MHRA, said the tablet had been authorised for use in people who have mild to moderate Covid and at least one risk factor for developing severe illness such as obesity, old age, diabetes or heart disease.

The organisation's chief executive, June Raine, described it as "another therapeutic to add to our armoury against Covid-19".

"It is the world's first approved antiviral for this disease that can be taken by mouth rather than administered intravenously," she said.

"This is important, because it means it can be administered outside of a hospital setting, before Covid-19 has progressed to a severe stage."

England's deputy chief medical officer, Prof Jonathan Van-Tam, warned on Wednesday of some "hard months to come" in the pandemic.

He said that while Covid cases appeared to have stabilised, deaths were rising and there were signs infections were starting to "penetrate" older age groups.

The UK recorded 41,242 Covid cases on Thursday and 214 deaths within 28 days of a positive test.


Clinical trials


Earlier clinical trials of molnupiravir on 775 patients who had recently caught Covid found:

*  7.3% of those given the drug were hospitalised

*  that compares with 14.1% of patients who were given a placebo or dummy pill

*  there were no deaths in the molnupiravir group, but eight patients who were given a placebo in the trial later died of Covid

The results were published in a press release and have not yet been peer-reviewed.

But data suggest molnupiravir needs to be taken soon after symptoms develop to have an effect. An earlier study in patients who had already been hospitalised with severe Covid was halted after disappointing results.

In its approval document, the MHRA recommends the drug is used "as soon as possible" following a positive Covid test and within five days of symptoms onset.

Prof Penny Ward, from King's College London, who was not involved in the study, said: "If these outcomes are replicated in the UK population, then the number of cases requiring hospital admission could be halved and the number of deaths greatly reduced.

"It seems likely that it will be restricted for use by those at highest risk of disease complications - for example older adults with heart, lung or kidney disease, diabetes or cancer."

The UK government has not disclosed how much its initial contract for 480,000 courses of molnupiravir is worth. But US authorities recently made an advance purchase of 1.7 million courses at a cost of roughly $1.2 billion, or $700 (£513) for each patient.

Other countries including Australia, Singapore and South Korea have also made purchase agreements.

Merck is the first company to report trial results of a pill to treat Covid, but other companies are working on similar treatments.

Its US rival Pfizer has started trials of two different antiviral tablets, while Swiss company Roche is working on a similar medication.

Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
China Accuses US of Violating Trade Truce
Panama Port Owner Balances US-China Pressures
France Implements Nationwide Outdoor Smoking Ban to Protect Children
German Chancellor Merz Keeps Putin Guessing on Missile Strategy
Mandelson Criticizes UK's 'Fetish' for Abandoning EU Regulations
British Fishing Boat Owner Fined €30,000 by French Authorities
Dutch government falls as far-right leader Wilders quits coalition
Harvard Urges US to Unfreeze Funds for Public Health Research
Businessman Mauled by Lion at Luxury Namibian Lodge
Researchers Consider New Destinations Beyond the U.S.
53-Year-Old Doctor Claims Biological Age of 23
Trump Struggles to Secure Trade Deals With China and Europe
Russia to Return 6,000 Corpses Under Ukraine Prisoner Swap Deal
Microsoft Lays Off Hundreds More Amid Restructuring
Harvey Weinstein’s Publicist Embraces Notoriety
Macron and Meloni Seek Unity Despite Tensions
Trump Administration Accused of Obstructing Deportation Cases
Newark Mayor Sues Over Arrest at Immigration Facility
Center-Left Candidate Projected to Win South Korean Presidency
Trump’s Tariffs Predicted to Stall Global Economic Growth
South Korea’s President-Elect Expected to Take Softer Line on Trump and North Korea
Trump’s China Strategy Remains a Geopolitical Puzzle
Ukraine Executes Long-Range Drone Strikes on Russian Airbases
Conservative Karol Nawrocki wins Poland’s presidential election
Study Identifies Potential Radicalization Risk Among Over One Million Muslims in Germany
Good news: Annalena Baerbock Elected President of the UN General Assembly
Apple Appeals EU Law Over User Data Sharing Requirements
South Africa: "First Black Bank" Collapses after Being Looted by Owners
Poland will now withdraw from the EU migration pact after pro-Trump nationalist wins Election
"That's Disgusting, Don’t Say It Again": The Trump Joke That Made the President Boil
Trump Cancels NASA Nominee Over Democratic Donations
Paris Saint-Germain's Greatest Triumph Is Football’s Lowest Point
OnlyFans for Sale: From Lockdown Lifeline to Eight-Billion-Dollar Empire
Mayor’s Security Officer Implicated | Shocking New Details Emerge in NYC Kidnapping Case
Hegseth Warns of Potential Chinese Military Action Against Taiwan
OPEC+ Agrees to Increase Oil Output for Third Consecutive Month
Jamie Dimon Warns U.S. Bond Market Faces Pressure from Rising Debt
Turkey Detains Istanbul Officials Amid Anti-Corruption Crackdown
Taylor Swift Gains Ownership of Her First Six Albums
Bangkok Ranked World's Top City for Remote Work in 2025
Satirical Sketch Sparks Political Spouse Feud in South Korea
Indonesia Quarry Collapse Leaves Multiple Dead and Missing
South Korean Election Video Pulled Amid Misogyny Outcry
Asian Economies Shift Away from US Dollar Amid Trade Tensions
Netflix Investigates Allegations of On-Set Mistreatment in K-Drama Production
US Defence Chief Reaffirms Strong Ties with Singapore Amid Regional Tensions
Vietnam Faces Strategic Dilemma Over China's Mekong River Projects
Malaysia's First AI Preacher Sparks Debate on Islamic Principles
White House Press Secretary Criticizes Harvard Funding, Advocates for Vocational Training
France to Implement Nationwide Smoking Ban in Outdoor Spaces Frequented by Children
×